Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.50.

APYX has been the subject of a number of research analyst reports. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th. Craig Hallum raised their target price on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC purchased a new stake in Apyx Medical during the 3rd quarter worth approximately $28,000. Caprock Group LLC acquired a new position in shares of Apyx Medical in the 3rd quarter valued at $40,000. Nwam LLC acquired a new position in shares of Apyx Medical in the 1st quarter valued at $47,000. Osaic Holdings Inc. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $50,000. Finally, Franklin Resources Inc. acquired a new position in shares of Apyx Medical in the 3rd quarter valued at $59,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Price Performance

Apyx Medical stock opened at $4.11 on Friday. Apyx Medical has a 12-month low of $1.59 and a 12-month high of $5.08. The firm has a 50-day moving average price of $3.98 and a 200-day moving average price of $3.83. The firm has a market capitalization of $172.09 million, a PE ratio of -18.68 and a beta of 1.39. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The company had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.53 million.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.